Medical/Pharmaceuticals
New Study Demonstrates Lunit SCOPE IO's Effectiveness to Predict Biliary Tract Cancer Therapy Outcomes - Findings to be Presented at the ESMO 2023
- Nine abstracts, featuring the effectiveness of Lunit's AI-powered TIL/WSI analyzer and biomarker platform, accepted by the ESMO 2023 Congress SEOUL, South Korea, Oct. 16, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeut...
2023-10-16 21:10
1574
Hong Kong Breast Cancer Foundation - "Pink Walk 2023" Charity Walk Concluded Successfully
Nearly 2,000 Pink Walkers returned to the Peak for Step Up for Breast Health HONG KONG, Oct. 16, 2023 /PRNewswire/ -- The annual flagship fundraising event, "Pink Walk 2023" organised by the Hong Kong Breast Cancer Foundation (HKBCF), was successfully held on 15 October in the Breast Cancer Aware...
2023-10-16 21:01
1879
TaiMed Announces Significant Progress in Clinical Trials for New HIV Treatment
Company champions long-acting HIV therapy with new biologic drug TMB-365/380
combination; after favorable results of Phase1b/2a, company plans to accelerate
Phase 2 clincial study to expedite path to market
TAIPEI, Oct. 16, 2023 /PRNewswire/ -- TaiMed Biologics
2023-10-16 21:00
1454
I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023
ROCKVILLE, Md. and SHANGHAI, China, Oct. 16, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapie...
2023-10-16 20:00
1743
SeekIn Presents New Validation Studies of OncoSeek Multi-cancer Early Detection test at Early Detection of Cancer Conference in London
Two Sample Types, Three Different Platforms, Five Independent Cohorts of ~10,000 Cancer Patients and Non-cancer Individuals with Diverse Ethnic Backgrounds Validate OncoSeek's Ability to Detect Multiple Cancer Types and Predict Tissue of Origin of Cancers SHENZHEN, China, Oct. 16, 2023 /PRNewswi...
2023-10-16 20:00
1444
Abbisko presented two preclinical research results at the 35th International Molecular Targets and Cancer Treatment Conference (EORTC-NCI-AACR)
SHANGHAI, Oct. 16, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko" hereafter) announced that the results of the company's two preclinical studies published at the 35th International Molecular Targets and Cancer Treatment Conference (EORTC) be held inBoston, U.S.. These two research...
2023-10-16 18:20
1539
Fapon and Halodoc Forge Strategic Partnership to Drive the Development of Indonesia's In-Vitro Diagnostics Industry
JAKARTA, Indonesia, Oct. 16, 2023 /PRNewswire/ -- On October 12th, 2023, Fapon, a leading life-science organization, signed a strategic cooperation agreement with Halodoc, the largest telehealth platform inIndonesia. This partnership brings together Fapon's expertise in in-vitro diagnostics (IVD)...
2023-10-16 15:29
2321
CANbridge Announces Full Enrollment Reached in the Core Part of The CAN103 Phase 2 Trial for Gaucher Disease in China
BEIJING and BURLINGTON, Mass., Oct. 16, 2023 /PRNewswire/ -- CANbridge Pharmaceuticals Inc. (1228.HK),a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative therapies to treat rare disease and rare oncology, ...
2023-10-16 13:38
1394
Ascentage Pharma and AstraZeneca Enter into Clinical Collaboration on the Registrational Phase III Study of Bcl-2 Inhibitor Lisaftoclax in Combination with BTK Inhibitor Acalabrutinib in Treatment-Naïve Patients with First-Line CLL/SLL
SUZHOU, China, and ROCKVILLE, Md., Oct. 15, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has entered into a clinical collaboration ...
2023-10-16 09:23
2027
Everest Medicines' Licensing Partner Pfizer Announces U.S. FDA Approves Etrasimod for Adults with Moderately to Severely Active Ulcerative Colitis
SHANGHAI, Oct. 16, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) announced today that its licensing partner, Pfizer Inc. (NYSE: PFE) has received approval from the U.S. Food and Drug Administration (FDA) for VELSIPITY™ (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (...
2023-10-16 07:48
1338
UEG Week 2023: Babies with a low birthweight four times more likely to develop fatty liver disease in later life
COPENHAGEN, Denmark, Oct. 16, 2023 /PRNewswire/ -- A groundbreaking new study, presented today at UEG Week 2023, has discovered a significant connection between birthweight and the onset of nonalcoholic fatty liver disease, now known as metabolic dysfunction-associated steatotic liver disease (MA...
2023-10-16 06:01
1972
HEALTHSCOPE : AI ENABLES PATIENT EMOTIONS TO BE ANALYSED IMPROVING HOSPITAL EXPERIENCE.
MELBOURNE, Australia, Oct. 16, 2023 /PRNewswire/ -- A new way to capture patients' emotions is being pioneered by Healthscope to improve how they deliver patient experience following a 3-year study, in what is believed to be a world first by a private hospital. Hospitals rely every day on data s...
2023-10-16 04:00
2349
Nona Biosciences and INGENIA Therapeutics Enter into Collaboration Agreement
CAMBRIDGE, Mass., Oct. 13, 2023 /PRNewswire/ -- Nona Biosciences, a global pioneer of technology innovation and antibody discovery and development solutions, and INGENIA Therapeutics, a preclinical-stage biotech company with a breakthrough technology to restore defective blood vessels, announced ...
2023-10-13 23:26
2690
Offering broader access to sustainable and scalable pharma-grade saponin adjuvants
SPI Pharma, Inc. and Q-Vant Biosciences, Inc. announce a strategic partnership which includes an investment to expand Q-Vant's proprietary 100% sustainable Q-SAP™ technology, and the signing of an exclusive commercial agreement to accelerate global adoption of their high-purity saponin adjuvants ...
2023-10-13 21:47
2711
Actinogen to present progress on Phase 2 trials at the BIO Investor Forum, San Francisco and Clinical Trials on Alzheimer's Disease (CTAD) Conference, Boston
Xanamem® is an oral, brain-penetrant tissue cortisol synthesis inhibitor that has shown promising safety and clinical activity in three placebo-controlled trials and has the potential to treat a variety of neurodegenerative and neuropsychiatric diseases SYDNEY, Oct. 13, 2023 /PRNewswire/ -- Acti...
2023-10-13 20:00
2398
Inmagene Doses First Patient in Phase 2a Trial of IMG-007, an Anti-OX40 Monoclonal Antibody with an Extended Half-life, for the Treatment of Alopecia Areata
* IMG-007 is a novel anti-OX40 monoclonal antibody (mAb) engineered for potentially once every 12 weeks dosing and an improved safety profile * IMG-007 is being evaluated for the treatment of alopecia areata (AA) and atopic dermatitis (AD) * An interim data readout in AA is expected in Q3 20...
2023-10-13 20:00
2027
World Thrombosis Day encourages public to "Move Against Thrombosis" to celebrate 10 years of raising awareness worldwide
CHAPEL HILL, N.C., Oct. 13, 2023 /PRNewswire/ -- Today is World Thrombosis Day, a global effort by the International Society on Thrombosis and Haemostasis (ISTH) to spread awareness of the signs, symptoms and risk factors of thrombosis, commonly known as blood clots. World Thrombosis Day engages...
2023-10-13 15:00
736
SK Biopharmaceuticals' Proteovant Therapeutics Presents Preclinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
New data presented on novel orally bioavailable p300-selective degraders showing significant anti-tumor activity in preclinical models of androgen receptor (AR) positive prostate cancer SEOUL, South Korea and KING OF PRUSSIA, Pa., Oct. 12, 2023 /PRNewswire/ -- SK Biopharmaceuticals, a global bio...
2023-10-13 09:00
1666
GenScript ProBio Congratulates ABL Bio's IND Clearance of ABL103 Program from MFDS
SEOUL, South Korea, Oct. 13, 2023 /PRNewswire/ -- Recently, ABL Bio, a partner of GenScript ProBio, announced the Ministry of Food and Drug Safety (MFDS) cleared of its clinical trial application for innovative bispecific antibody program (B7H4x4-1BB) in solid tumor. GenScript ProBio warmly exten...
2023-10-13 09:00
2284
Global Registrational Phase III Study of Bcl-2 Inhibitor Lisaftoclax in Treatment-Naïve Patients with CLL/SLL Approved by the China CDE
ROCKVILLE, Md. and SUZHOU, China, Oct. 12, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the Center for Drug Evaluation (CDE) of China ...
2023-10-13 08:22
1714
Week's Top Stories
Most Reposted
QDX Co-Founder Giuseppe Barca Awarded Prestigious Gordon Bell Prize, Pioneering Advancements in Drug Discovery Technology
[Picked up by 303 media titles]
2024-11-26 18:49ITAP 2024 sets the stage for a more connected advanced factory ecosystem with focus on AI, advanced robotics and sustainability
[Picked up by 296 media titles]
2024-11-28 17:24Southeast Asian Consumers Raise Online Security Concerns, New GSMA Survey Shows
[Picked up by 296 media titles]
2024-11-26 13:00MediSun Energy Raises $8.75M Seed Round with Vynn Capital to Drive MENA Expansion and Advance Osmotic Energy Innovation
[Picked up by 280 media titles]
2024-11-25 10:00
Mentech at COP29: Showing the Eco-friendly Lifestyle with Technological Innovation
[Picked up by 274 media titles]
2024-11-29 20:33
Most Read
Chinese path to modernization a model for Global South, experts say
2024-11-23 15:35
13780
SUNLU Formnext 2024 Event Highlights: From Functional Filaments to FilaDryer E2
2024-11-23 21:00
9866
Innovative technology and applications recognised with Hong Kong ICT Awards 2024
2024-11-23 02:02
8334
